384 (38%) and 150 (39%) of the patients of the 2002- and 2017-cohort were female, patients from the 2017-cohort showed a slightly higher LVEF (36 vs 34%, p < 0.001), had lower rates of severe HF (NYHA III-IV) and lower levels of NT-proBNP (1944 vs 2528 ng/L, p < 0.001) compared to patients from the 2002-cohort. This evidence concerns the gene NPPB and hydrops fetalis.